InnoSer partners with CR2O to offer an integrated drug discovery to clinical trials pipeline. Researchers benefit from a comprehensive service offering, spanning early-stage discovery to phase I-IV trials, with meticulous planning and access to specialized services, aiming to set a new standard for excellence in the industry. Diepenbeek, Belgium and…
PDC*line Pharma and partners receive €8.1M from Walloon region and Wallonia health cluster BioWin for personalized therapeutic vaccine project PDC*neo+ project aims to develop personalized therapeutic vaccine based on neoantigens for colorectal cancer Collaborative effort between biotechnology companies, PDC*line Pharma and OncoDNA, technology company salamanderU and universities UCLouvain–IREC/MIRO and ULB-BCTL…
Biocair announces US expansion as part of global growth strategy Following a period of sustained growth, life science logistics company Biocair has relocated and expanded its Chicago office and warehouse facility. As part of its wider global growth strategy, the leading specialist has increased its 2,904 sq. ft. space by…
Bioxodes closes €12 million in Series A funding round Funding will enable Bioxodes to continue clinical development of drug candidate for patients with intracerebral hemorrhage Recruitment of first patient for phase IIa proof-of-concept clinical trial due before end of Q4, 2023 Gosselies, Belgium, November 21, 2023 – Bioxodes SA, a biopharmaceutical company specializing…
COVARTIM settles at LégiaPark and reinforces its links with the MedTech ecosystem in Liège area Liège, October 10, 2023 – COVARTIM, a Belgian engineering company focusing on the development and the certification of medical technologies, is getting closer to Liège manufacturers by opening a new office at LégiaPark. The company…
AbolerIS Pharma Announces €27 Million in Series A Financing to Advance its Novel Treatment Paradigm for Autoimmune and Inflammatory Diseases Financing round led by Caixa Capital Risc and co-led by Sound Bioventures and existing investor Newton Biocapital. AbolerIS is developing a first-in-class drug inducing an immune tolerance-based mechanism that acts…
Artialis appoints Benedikt Van Nieuwenhove as its new CEO August 1st, 2023 Liège, Belgium – Artialis SA, a CRDO company offering preclinical, clinical and biotesting services, is pleased to announce Benedikt Van Nieuwenhove as its new Chief Executive Officer (CEO). Prof. Yves Henrotin, founder and former CEO of the company, will…
Mont-Saint-Guibert, Belgium, 2023/06/20: Cellaïon is a biotechnology company based in Mont-St-Guibert, active in the field of liver regenerative advanced therapy, an area of excellence in the life sciences industry in Wallonia. Its flagship product HepaStem®, in advanced clinical development, targets severe liver diseases, and in particular Acute on Chronic Liver…